July 21, 2016
1 min read

Seven updates in sarcoma treatment, research

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

An estimated 12,310 people in the United States will be diagnosed with soft tissue sarcomas this year, and 4,990 Americans will die of the disease, according to the American Cancer Society.

In conjunction with Sarcoma Awareness Month, HemOnc Today presents seven updates in sarcoma treatment and research.

  • The FDA granted orphan drug designation to TK216 (Oncternal Therapeutics) for the treatment of Ewing sarcoma, a rare pediatric cancer comprised of highly malignant, undifferentiated tumors of bone. Read more
  • Gary K. Schwartz, MD, chief of hematology and oncology at Columbia University Medical Center, reviews data presented at the ASCO Annual Meeting that show how immunotherapy can treat various sarcoma subtypes. Watch here
  • Older patients with soft tissue sarcoma derived more benefit from adjuvant radiation than younger patients, according to retrospective study results. Read more
  • NY-ESO-1–specific T cells demonstrated clinical activity and appeared to induce disease regression when used for the treatment of synovial sarcoma and myxoid/round-cell liposarcoma. Seth M. Pollack, MD, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, provides insights in this video. Watch here
  • The addition of olaratumab (LY3012207, Eli Lilly) to doxorubicin significantly prolonged OS in patients with advanced soft tissue sarcoma, according to phase 2 study results. Read more
  • Gary K. Schwartz, MD, chief of hematology and oncology at NewYork-Presbyterian/Columbia University Medical Center, spoke with HemOnc Today at the ASCO Annual Meeting about research that evaluated treatments for sarcoma that target receptor tyrosine kinases. Watch here.
  • The TP53 gene mutation may predict improved response to VEGF receptor inhibition among patients with advanced sarcomas, according to a retrospective chart review. Read more